- Zacks•16 days ago
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
Merrimack Pharmaceuticals, Inc.NasdaqGM
After hours: 5.750.25 (4.55%) as of 6:04 PM EDT
|Bid||5.48 x 100|
|Ask||6.00 x 200|
|52wk Range||5.02 - 11.18|
|Day's Range||5.37 - 5.61|
|Avg Vol (3m)||1,722,053|
As of 4:00 PM EDT. Market closed.